Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYAI OTCMKTS:INTI NASDAQ:MDCX NASDAQ:MRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.96-3.2%$0.95$0.71▼$2.20$35.28M0.9482,931 shs37,723 shsINTIInhibitor Therapeutics$0.04-6.3%$0.05$0.03▼$0.10$7.42M-0.3828,492 shs5,730 shsMDCXMedicus Pharma$2.36+4.9%$2.46$1.79▼$8.94$42.06MN/A235,408 shs171,614 shsMRSNMersana Therapeutics$7.17-4.0%$7.55$5.21▼$70.75$35.65M0.87152,114 shs21,878 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International+1.00%+3.43%+16.44%+5.29%-20.82%INTIInhibitor Therapeutics0.00%+20.47%-6.33%-5.36%-42.63%MDCXMedicus Pharma+10.84%+22.95%+0.45%-13.46%+224,999,900.00%MRSNMersana Therapeutics+1.63%+4.92%+23.06%-18.63%-83.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.96-3.2%$0.95$0.71▼$2.20$35.28M0.9482,931 shs37,723 shsINTIInhibitor Therapeutics$0.04-6.3%$0.05$0.03▼$0.10$7.42M-0.3828,492 shs5,730 shsMDCXMedicus Pharma$2.36+4.9%$2.46$1.79▼$8.94$42.06MN/A235,408 shs171,614 shsMRSNMersana Therapeutics$7.17-4.0%$7.55$5.21▼$70.75$35.65M0.87152,114 shs21,878 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International+1.00%+3.43%+16.44%+5.29%-20.82%INTIInhibitor Therapeutics0.00%+20.47%-6.33%-5.36%-42.63%MDCXMedicus Pharma+10.84%+22.95%+0.45%-13.46%+224,999,900.00%MRSNMersana Therapeutics+1.63%+4.92%+23.06%-18.63%-83.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYAIDyadic International 3.00Buy$6.00511.00% UpsideINTIInhibitor Therapeutics 0.00N/AN/AN/AMDCXMedicus Pharma 3.50Strong Buy$23.50958.56% UpsideMRSNMersana Therapeutics 3.00Buy$56.60666.00% UpsideCurrent Analyst Ratings BreakdownLatest INTI, MRSN, MDCX, and DYAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DYAIDyadic InternationalCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/2/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/14/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $36.008/14/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$125.00 ➝ $30.008/13/2025MRSNMersana TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.008/13/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.007/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.007/1/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.006/23/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYAIDyadic International$3.42M10.39N/AN/A$0.08 per share12.28INTIInhibitor TherapeuticsN/AN/AN/AN/A$0.01 per shareN/AMDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/AMRSNMersana Therapeutics$40.50M0.91N/AN/A($1.92) per share-3.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYAIDyadic International-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)INTIInhibitor Therapeutics-$3.34M-$0.01N/A∞N/AN/A-184.77%-67.05%11/10/2025 (Estimated)MDCXMedicus Pharma-$11.16M-$1.34N/AN/AN/AN/A-549.30%-228.06%11/28/2025 (Estimated)MRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%-990.16%-54.85%11/12/2025 (Estimated)Latest INTI, MRSN, MDCX, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 million8/11/2025Q2 2025MDCXMedicus Pharma-$0.39-$0.43-$0.04-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYAIDyadic InternationalN/AN/AN/AN/AN/AINTIInhibitor TherapeuticsN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYAIDyadic International5.402.022.02INTIInhibitor TherapeuticsN/A27.3627.36MDCXMedicus PharmaN/A1.291.29MRSNMersana TherapeuticsN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYAIDyadic International27.95%INTIInhibitor TherapeuticsN/AMDCXMedicus PharmaN/AMRSNMersana Therapeutics93.92%Insider OwnershipCompanyInsider OwnershipDYAIDyadic International29.50%INTIInhibitor Therapeutics4.60%MDCXMedicus Pharma11.20%MRSNMersana Therapeutics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYAIDyadic International736.19 million25.51 millionOptionableINTIInhibitor Therapeutics1172.57 million164.64 millionNot OptionableMDCXMedicus PharmaN/A17.82 million15.82 millionN/AMRSNMersana Therapeutics1504.99 million4.34 millionOptionableINTI, MRSN, MDCX, and DYAI HeadlinesRecent News About These CompaniesWall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?September 8, 2025 | zacks.comMersana Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 6, 2025 | msn.comWall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a BetAugust 22, 2025 | zacks.comMersana Therapeutics price target adjusted to $36 at Truist after reverse splitAugust 14, 2025 | msn.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comMersana Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comMersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)August 13, 2025 | msn.comMersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deMersana Misses Fiscal Q2 Revenue TargetAugust 13, 2025 | theglobeandmail.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | finance.yahoo.comMersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue EstimatesAugust 13, 2025 | zacks.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comMersana Therapeutics Q2 2025 Earnings PreviewAugust 12, 2025 | msn.comA Look at Mersana Therapeutics's Upcoming Earnings ReportAugust 12, 2025 | benzinga.comEarnings To Watch: Mersana Therapeutics Inc (MRSN) Reports Q2 2025 ResultAugust 12, 2025 | finance.yahoo.comMersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025August 6, 2025 | globenewswire.comMersana Therapeutics trading halted, news pendingJuly 26, 2025 | msn.comMersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025July 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINTI, MRSN, MDCX, and DYAI Company DescriptionsDyadic International NASDAQ:DYAI$0.96 -0.03 (-3.20%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Inhibitor Therapeutics OTCMKTS:INTI$0.04 0.00 (-6.32%) As of 02:00 PM EasternInhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.Medicus Pharma NASDAQ:MDCX$2.36 +0.11 (+4.89%) As of 03:33 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Mersana Therapeutics NASDAQ:MRSN$7.17 -0.30 (-4.02%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
